PRT2527
A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With Relapsed/Refractory Hematologic Malignancies
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 274 patients (estimated)
- Sponsors
- Prelude Therapeutics
- Collaborators
- BeiGene
- Tags
- Cyclin-Dependent Kinase Inhibitor (CDK Inhibitor)
- Trial Type
- Treatment
- Last Update
- 1 week ago
- SparkCures ID
- 1989
- NCT Identifier
- NCT05665530
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.